CLINICAL_TRIALS
trial_result
· 2016-12-06
Clinical Trial Update: Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients [Phase 2]
Summary
The Phase 2 safety and efficacy study of Q301 for moderate to severe atopic dermatitis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Qurient Co., Ltd. | Conditions: Moderate to Severe Atopic Dermatitis | Phase 2 | Status: COMPLETED